Isomorphic Labs Prepares for Landmark Human Trials of AI-Designed Drugs
Isomorphic Labs Prepares for Landmark Human Trials of AI-Designed Drugs
Alphabet’s secretive drug discovery arm, Isomorphic Labs, is on the cusp of a major breakthrough, gearing up to commence human clinical trials for its groundbreaking AI-designed pharmaceuticals. This pivotal development marks a significant step towards realizing the company’s ambitious goal of revolutionizing medicine through artificial intelligence.
Colin Murdoch, President of Isomorphic Labs and Chief Business Officer of Google DeepMind, confirmed that teams are actively working with AI to design drugs, including for cancer, and are ‘very close’ to initiating trials. He stated, ‘The next big milestone is actually going out to clinical trials, starting to put these things into human beings.’
Spun out of DeepMind in 2021, Isomorphic Labs leverages the power of AlphaFold, DeepMind’s celebrated AI system capable of predicting protein structures. This technology has evolved to model complex protein interactions, dramatically enhancing drug design capabilities.
The company has rapidly advanced, securing major research collaborations with pharmaceutical giants Novartis and Eli Lilly in 2024, and raising a substantial $600 million in its first external funding round in April 2025, led by Thrive Capital. These initiatives underscore Isomorphic Labs’ commitment to building a world-class AI-powered drug design engine that promises to accelerate development, reduce costs, and significantly improve success rates in bringing new medicines to market.
Disclaimer: This content is aggregated from public sources online. Please verify information independently. If you believe your rights have been infringed, contact us for removal.